ScholarMate
English简体中文繁體中文
客服热线:400-1616-289
登录注册
期刊论文

The efficacy and safety of apatinib plus capecitabine in platinum-refractory metastatic and/or recurrent nasopharyngeal carcinoma: a prospective, phase II trial

Tang, Lin-Quan; Li, Xiao-Yun; Li, Zhi-Ming; Liu, Zhi-Gang; Lin, Miao-Zhen; Zhou, Huan; Yu, Qi-Wen; Zhou, Jian; Zhao, Chong; Chen, Ze-Bin; Wang, Xi-Cheng; Peng, Jia-Yu; Chen, Qiu-Yan; Fang, Wen-Feng; Yang, Yun-Peng; Zhang, Bei; Xia, Liang-Ping; Hu, Pi-Li; Hu, Wei-Han; Li, Yi-Jie; Mai, Hai-Qiang; Cai, Xiu-Yu*广东药学院; 中山大学; 1; 5
BMC Medicine2023-3-16DOI: 10.1186/s12916-023-02790-1
12阅读
引用收藏
分享

摘要

BackgroundPrevious studies have shown that monotherapy with apatinib, an oral tyrosine kinase inhibitor, has promising efficacy for treating recurrent or metastatic (RM) nasopharyngeal carcinoma (NPC) patients. In this study, we aimed to assess the efficacy and safety of apatinib combined with capecitabine as a second-line therapy or beyond for treating RM-NPC patients who failed the first-line platinum-based chemotherapy.MethodsIn this single-arm, phase II study, we enrolled RM-NPC patients who had at least one measurable lesion according to the Response Evaluation Criteria in Solid Tumors (RECIST v1.1). The sample size was determined using Simon's two-stage design. All patients were administered with apatinib 500 mg once daily and capecitabine 1000 mg/m(2) twice per day on days 1-14 of each 21-day cycle. The primary endpoint was the objective response rate (ORR), and the secondary endpoints comprised disease control rate (DCR), duration of response (DoR), progression-free survival (PFS), overall survival (OS), and safety.ResultsWe enrolled 64 patients from September 2018 to August 2020. The ORR and DCR were 39.1% (95% CI, 27.1-52.1) and 85.9% (95% CI, 75.0-93.4), respectively. The median DoR was 14.4 months (95% CI, 7.8-21.0). As of April 20, 2021, the median follow-up duration was 12.0 months. The median PFS was 7.5 months (95% CI, 5.0-10.0) and the median OS was 15.7 months (95% CI, 11.3-20.1). The most common toxicities of any grade were anemia (75.0%), hand-foot syndrome (65.6%), and proteinuria (64.0%). Grade 3-4 toxicities were observed in 36 (56.3%) patients, with hypertension (14.1%), mucositis (12.4%), and fatigue (10.9%) most commonly observed.ConclusionsApatinib plus capecitabine shows promising efficacy as a second-line treatment option in pretreated platinum-refractory RM-NPC patients. Dose selection of this combination needs further investigation considering the toxicity.

学科与关键词

关键词
Nasopharyngeal carcinomaTyrosine kinase inhibitorApatinib
相关
加载中…
  • Camrelizumab Plus Apatinib in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma: An Open-Label, Single-Arm, Phase II Study
    Ding, Xi; Zhang, Wei-Jing; You, Rui; Zou, Xiong; Wang, Zhi-Qiang; Ouyang, Yan-Feng; Peng, Lan; Liu, You-Ping; Duan, Chong-Yang; Yang, Qi; Lin, Chao; Xie, Yu-Long; Chen, Si-Yuan; Liu, Yong-Long; Gu, Chen-Mei; Xie, Ruo-Qi; Huang, Pei-Yu; Hong, Ming-Huang; Hua, Yi-Jun; Chen, Ming-YuanJournal of Clinical Oncology, 2023, 41(14): 2571-+.被引 15
  • 吉西他滨联合阿帕替尼二线治疗复发转移性鼻咽癌疗效及安全性分析
    陈少卿; 黎军和; 余永春; 胡明斌; 刘运炜; 严俊峰Chinese Journal of Cancer Prevention and Treatment, 2019, (20): 1547-1550.
  • Evaluation of second-line apatinib plus irinotecan as a treatment for advanced gastric adenocarcinoma or gastroesophageal conjunction adenocarcinoma: a prospective, multicenter phase II trial
    Qu, Jinglei; He, Xin; Luo, Ying; Yu, Ping; Chen, Ying; Liu, Jing; Wang, Xin; Wang, Chang; Liang, Tingting; Bai, Yuxian; Han, Yu; Man, Li; Leng, Chuanchun; Zhou, Caiyun; He, Lijie; Liu, Yunpeng*; Qu, Xiujuan*Frontiers in Oncology, 2023, 13: 1072943.
查看全部 →

发表信息

论文状态
公开发表
期刊
BMC Medicine
发表日期
2023-03-16
卷期
第 21 卷, 第 1 期
页码
94
DOI
10.1186/s12916-023-02790-1
语言
ENGLISH
成果收录
SCIE

作者

  • T

    Tang, Lin-Quan (第一作者)

    sun yat sen univ

  • L

    Li, Xiao-Yun

    sun yat sen univ

查看全部 22 位作者收起作者
  • L

    Li, Zhi-Ming

    sun yat sen univ

  • L

    Liu, Zhi-Gang

    5 · sun yat sen univ

  • L

    Lin, Miao-Zhen

    sun yat sen univ

  • Z

    Zhou, Huan

    1 · guangdong pharmaceut univ

  • Y

    Yu, Qi-Wen

    1 · guangdong pharmaceut univ

  • Z

    Zhou, Jian

    sun yat sen univ

  • Z

    Zhao, Chong

    sun yat sen univ

  • C

    Chen, Ze-Bin

    1 · guangdong pharmaceut univ

  • W

    Wang, Xi-Cheng

    1 · guangdong pharmaceut univ

  • P

    Peng, Jia-Yu

    1 · guangdong pharmaceut univ

  • C

    Chen, Qiu-Yan

    sun yat sen univ

  • F

    Fang, Wen-Feng

    sun yat sen univ

  • Y

    Yang, Yun-Peng

    sun yat sen univ

  • Z

    Zhang, Bei

    sun yat sen univ

  • X

    Xia, Liang-Ping

    sun yat sen univ

  • H

    Hu, Pi-Li

    sun yat sen univ

  • H

    Hu, Wei-Han

    sun yat sen univ

  • L

    Li, Yi-Jie

  • M

    Mai, Hai-Qiang

    sun yat sen univ

  • C

    Cai, Xiu-Yu (通讯)

    sun yat sen univ

登录解锁更多功能

  • 收藏这篇,随时在“我的 · 收藏”找回
  • 认领你的成果,生成推广素材
  • 关注作者获取最新成果
  • 加入项目组、协同写作
注册 / 登录

产品服务

  • 科研之友
  • 创新城
  • 科创云

服务支持

  • 帮助中心
  • 隐私政策
  • 服务条款

联系方式

在线客服:【】
客服热线:400-1616-289
电子邮箱:support@scholarmate.com

关注或下载科研之友

微信二维码
微信公众号
客户端下载二维码
下载客户端
科研成果科研人员科研机构科研动态爱瑞思软件

©2026 深圳市科研之友网络服务有限公司

公安备案图标粤公网安备 44030502000213
粤ICP备 16046710 号粤B2-20110417